Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
Oral semaglutide appeared to be associated with a lower 1-year risk of all-cause death compared with sitagliptin in patients with HFpEF and T2D.
Authors
- Takefumi Kishimori (ORCID: https://orcid.org/0009-0000-9639-5470)
- R Yamaji
- Arisa Wada
- Jumpei Koike
- Masaharu Okada
- Takehiro Matsumoto (ORCID: https://orcid.org/0000-0002-0379-5334)
- Takenobu Shimada (ORCID: https://orcid.org/0000-0002-6300-9112)
- Yoshihiro Iwasaki
- Akira Tani
- T. Kato
- Takafumi Yagi
Institutions
- Kansai Medical University (JP)
- Kyoto University (JP)
- Osaka Metropolitan University (JP)
- Tokyo Metropolitan University (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1111/dom.70433
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00